Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies;Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE)

Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies;Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE)